Is UK pharma really ‘uninvestable’?

Cancelled or paused investments in UK pharmaceutical R&D – from Merck & Co, AstraZeneca (AZ), Eli Lilly and others – highlight the precarious position of the country’s life sciences industry. The UK has a world-class academic base in its universities and research institutes, but that alone isn’t enough to convince multinational companies to choose to invest in UK facilities rather than elsewhere.